|
1
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684.
2005.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Johnston SRD and Dowsett M: Aromatase
inhibitors for breast cancer: Lessons from the laboratory. Nat Rev
Cancer. 3:821–831. 2003.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Lee KW, Bode AM and Dong Z: Molecular
targets of phytochemicals for cancer prevention. Nat Rev Cancer.
11:211–218. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Ye I, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of breast cancer and cancer metastasis.
Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Telang NT, Katdare M, Bradlow HL, Osborne
MP and Fishman J: Inhibition of proliferation and modulation of
estradiol metabolism: Novel mechanisms for breast cancer prevention
by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med.
216:246–252. 1997.PubMed/NCBI
|
|
9
|
Subbaramaiah K, Chung WJ, Michaluart P,
Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ:
Resveratrol inhibits cyclooxygenase-2 transcription and activity in
phorbol ester-treated human mammary epithelial cells. J Biol Chem.
273:21875–21882. 1998.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Katdare M, Osborne M and Telang NT: Soy
isoflavone genistein modulates cell cycle progression and induces
apoptosis in HER-2/neu oncogene expressing human breast epithelial
cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Katdare M, Osborne MP and Telang NT: Novel
cell culture models for prevention of human breast cancer (Review).
Int J Oncol. 22:509–515. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jinno H, Steiner MG, Nason-Burchenal K,
Osborne MP and Telang NT: Preventive efficacy of receptor class
selective retinoids on HER-2/neu oncogene expressing preneoplastic
human mammary epithelial cells. Int J Oncol. 21:127–134.
2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Subbaramaiah K, Cole PA and Dannenberg AJ:
Retinoids and carnosol suppress cyclooxygenase-2 transcription by
CREB-binding protein/p300-dependent and -independent mechanisms.
Cancer Res. 62:2522–2530. 2002.PubMed/NCBI
|
|
14
|
Subbaramaiah K, Michaluart P, Sporn MB and
Dannenberg AJ: Ursolic acid inhibits cyclooxygenase-2 transcription
in human mammary epithelial cells. Cancer Res. 60:2399–2404.
2000.PubMed/NCBI
|
|
15
|
Telang N: Anti-proliferative and
pro-apoptotic effects of rosemary and constituent terpenoids in a
model for the HER-2-enriched molecular subtype of clinical breast
cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284.
2005.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Patel SA, Ndabahaliye A, Lim PK, Milton R
and Rameshwar P: Challenges in the development of future treatments
for breast cancer stem cells. Breast Cancer (Dove Med Press).
2:1–11. 2010.PubMed/NCBI
|
|
18
|
Yang F, Zhang J and Yang H: OCT4, SOX2,
and NANOG positive expression correlates with poor differentiation,
advanced disease stages, and worse overall survival in HER2+ breast
cancer patients. OncoTargets Ther. 11:7873–7881. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Telang N: Putative cancer-initiating stem
cells in cell culture models for molecular subtypes of clinical
breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Telang N: Growth inhibitory efficacy of
natural products in a model for triple negative molecular subtype
of clinical breast cancer. Biomed Rep. 7:199–204. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Telang N: Stem cell targeted therapeutic
approaches for molecular subtypes of clinical breast cancer. World
Acad Sci J. 1:20–24. 2019. View Article : Google Scholar
|
|
22
|
Zhai YF, Beittenmiller H, Wang B, Gould
MN, Oakley C, Esselman WJ and Welsch CW: Increased expression of
specific protein tyrosine phosphatases in human breast epithelial
cells neoplastically transformed by the neu oncogene. Cancer Res.
53:2272–2278. 1993.PubMed/NCBI
|
|
23
|
Rusnak DW, Lackey K, Affleck K, Wood ER,
Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ
and Gilmer TM: The effects of the novel, reversible epidermal
growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on
the growth of human normal and tumor-derived cell lines in
vitro and in vivo. Mol Cancer Ther. 1:85–94.
2001.PubMed/NCBI
|
|
24
|
Nahta R, Yuan LXH, Du Y and Esteva FJ:
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer
cells: Effects on insulin-like growth factor I signaling. Mol
Cancer Ther. 6:667–674. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Takahashi K, Tanabe K, Ohnuki M, Narita M,
Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Park IH, Zhao R, West JA, Yabuuchi A, Huo
H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of
human somatic cells to pluripotency with defined factors. Nature.
451:141–146. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yu J, Hu K, Smuga-Otto K, Tian S, Stewart
R, Slukvin II and Thomson JA: Human induced pluripotent stem cells
free of vector and transgene sequences. Science. 324:797–801.
2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nguyen PH, Giraud J, Staedel C,
Chambonnier L, Dubus P, Chevret E, Bœuf H, Gauthereau X, Rousseau
B, Fevre M, et al: All-trans retinoic acid targets gastric cancer
stem cells and inhibits patient-derived gastric carcinoma tumor
growth. Oncogene. 35:5619–5628. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kallifatidis G, Labsch S, Rausch V,
Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV and
Herr I, Sainikov AV and Herr I: Sulforaphane increases
drug-mediated cytotoxicity toward cancer stem-like cells of
pancreas and prostate. Mol Ther. 19:188–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhou W, Kallifatidis G, Baumann B, Rausch
V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler
MW and Herr I: Dietary polyphenol quercetin targets pancreatic
cancer stem cells. Int J Oncol. 37:551–561. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rausch V, Liu L, Kallifatidis G, Baumann
B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller
M, et al: Synergistic activity of sorafenib and sulforaphane
abolishes pancreatic cancer stem cell characteristics. Cancer Res.
70:5004–5013. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Castro NP, Rangel MC, Merchant AS,
MacKinnon G, Cuttitta F, Salomon DA and Kim YS: Sulforaphane
suppresses the growth of triple negative breast cancer stem-like
cells in vitro and in vivo. Cancer Prev Res (Phila).
12:147–158. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim SH and Singh SV: Role of Kruppel-like
factor 4-p21CIP1 axis in breast cancer stem-like cell
inhibition by benzyl isothiocyanate. Cancer Prev Res (Phila).
12:125–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bruna A, Rueda OM, Greenwood W, Batra AS,
Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW,
Tufegdzic-Vidakovic A, et al: A biobank of breast cancer explants
with preserved intra-tumor heterogeneity to screen anti-cancer
compounds. Cell. 167:260–274, e22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber E, Balgobind AV, Wind K, Gracanin A, et al: A
living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386, e10. 2018.PubMed/NCBI View Article : Google Scholar
|
